The FDA has approved Somatuline Depot (lanreotide) injection 120 mg for the treatment of carcinoid syndrome.
Indications: Somatuline Depot is a somatostatin analog indicated for the treatment of adults with carcinoid syndrome; it reduces the frequency of short-acting somatostatin analogue rescue therapy.
Dosage and administration: 120 mg every 4 weeks. Do not administer an additional dose if patients are already using it for gastroenteropancreatic neuroendocrine tumors.
Efficacy and safety: Approval is based on results showing patients receiving the medication experienced 15% fewer days on rescue medication compared to patients taking placebo.
Side effects/risks: The most common adverse reactions are headache, dizziness and muscle spasm.
Somatuline Depot [package insert]. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc. 2017. http://net.somatulinedepot.com/Static/PDF/Somatuline-Depot-Full-Prescrib.... Accessed October 1, 2017.
This Week's Must Reads
Durvalumab Post-Chemoradiotherapy in NSCLC Assessed, N Engl J Med; ePub 2017 Sep 8; Antonia, et al
Cochrane on Detecting CRC in Patients with IBD, Cochrane; 2017 Sep 18; Bye, Nguyen, Parker, et al
Lymph Node Removal During Endometrial Ca Surgery, Cochrane; 2017 Oct 2; Frost, Webster, et al
Cochrane on Reducing Neoplasia in Molar Pregnancy, Cochrane; 2017 Sep 11; Wang, Fu, Hu, et al
Cochrane on Reconstructing the Pancreatic Stump, Cochrane; 2017 Sep 12; Cheng, Briarava, et al
Must Reads in FDA Actions
FDA Approves Keytruda for Advanced Gastric Ca, Merck news release; 2017 Sep 22
FDA Approves Opdivo for Hepatocellular Carcinoma, Bristol-Myers Squibb news release; 2017 Sep 22
New Indication for Somatuline Depot, Ipsen package insert; 2017 Sep
Verzenio Approved for Certain Breast Cancers, FDA news release; 2017 Sep 28
FDA Approves First Biosimilar to Treat Cancer, FDA news release; 2017 Sep 14